Page 2 - Results Expected News Today

- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 -- Clearside Biomedical,... | June 1, 2023

Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in... | April 26, 2023

- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga.,...

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN,...

The CBSE roll numbers and admit cards would be released by the board in January and the CBSE Results 2023 are expected by end of May 2023. For more details, the students should check the official website cbse.nic.in.

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

Share: Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard ® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disea...

Xenikos B.V.: Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnolog...